株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

素因バイオマーカー:技術と世界市場

Predisposition Biomarkers: Technologies and Global Markets

発行 BCC Research 商品コード 914288
出版日 ページ情報 英文 72 Pages
即納可能
価格
本日の銀行送金レート: 1USD=110.56円で換算しております。
Back to Top
素因バイオマーカー:技術と世界市場 Predisposition Biomarkers: Technologies and Global Markets
出版日: 2019年10月17日 ページ情報: 英文 72 Pages
概要

当レポートでは、世界の素因バイオマーカー市場について調査し、技術と世界市場の概要、世界市場の動向とCAGR (年間複合成長率) 予測、各種素因バイオマーカーにおける近年の主な技術進歩および民間顧客・規制当局による導入の程度、主な成長領域の特定と主要企業の主な戦略などについて分析しています。

第1章 イントロダクション

第2章 サマリー・ハイライト

第3章 市場・技術背景

  • 市場定義

第4章 市場分析:エンドユーザー別

  • 病院
  • 研究機関

第5章 市場分析:用途別

  • 神経疾患
  • 心血管疾患
  • 糖尿病
  • その他の疾患

第6章 市場分析:地域別

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • その他の欧州
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • その他のアジア太平洋
  • その他 (RoW)

第7章 特許レビュー・新たな発展

  • 近年の発展

第8章 競合情勢

  • BioMerieux Inc.
  • F. Hoffmann-La Roche Ltd.
  • Merck KGaA
  • QIAGEN N.V.
  • Thermo Fisher Scientific Inc.
  • Myriad Genetics Inc.

第9章 企業プロファイル

  • ABCODIA LTD.
  • ADMERA HEALTH
  • ADX NEUROSCIENCES NV
  • AMPRION INC.
  • BIO-RAD LABORATORIES INC.
  • COMPUGEN LTD.
  • EPIGENOMICS AG
  • MIRNAXBIOSENS, S.L
  • ONCIMMUNE LTD.
  • OPTOS PLC
図表

List of Tables

  • Summary Table: Global Market for Predisposition Biomarkers, by Application, Through 2024
    • Table 1: Global Market for Predisposition Biomarkers, by End User, Through 2024
    • Table 2: Global Market for the Application of Predisposition Biomarkers in Hospitals, by Region, Through 2024
    • Table 3: Global Market for the Application of Predisposition Biomarkers in Research Institutes by Region, Through 2024
    • Table 4: Research Institutes Working on Cancer Studies Across the Globe
    • Table 5: Global Market for Predisposition Biomarkers, by Application, Through 2024
    • Table 6: Clinically Relevant Biomarkers for Lung Cancer
    • Table 7: Global Market for Cancer Predisposition Biomarkers, by Region, Through 2024
    • Table 8: Global Incidence and Prevalence of Common Neurological Diseases, 2017
    • Table 9: Global Market for Neurological Predisposition Biomarkers, by Region, Through 2024
    • Table 10: List of Biomarkers Associated with CVDs
    • Table 11: Global Market for Predisposition Biomarkers for CVDs, by Region, Through 2024
    • Table 12: Global Market for Diabetes Predisposition Biomarkers, by Region, Through 2024
    • Table 13: Characteristics of Biomarkers for Prediabetes, Diabetes and Associated Complications
    • Table 14: Global Market for Other Applications of Predisposition Biomarkers, by Region, Through 2024
    • Table 15: Global Market for Predisposition Biomarkers, by Region, Through 2024
    • Table 16: North American Market for Predisposition Biomarkers, by Country, Through 2024
    • Table 17: North American Market for Predisposition Biomarkers, by End User, Through 2024
    • Table 18: North American Market for Predisposition Biomarkers, by Application, Through 2024
    • Table 19: Active Early Detection Research Network Grants in the U.S., 2019
    • Table 20: Funding for Research on Biomarkers for Alzheimer's in Canada
    • Table 21: European Market for Predisposition Biomarkers, by Country, Through 2024
    • Table 22: European Market for Predisposition Biomarkers, by End User, Through 2024
    • Table 23: European Market for Predisposition Biomarkers, by Application, Through 2024
    • Table 24: Cancer Incidences and Mortalities in Europe, 2018
    • Table 25: Major Neurological Incidences in Europe in 2017
    • Table 26: Asia-Pacific Market for Predisposition Biomarkers, by Country, Through 2024
    • Table 27: Asia-Pacific Market for Predisposition Biomarkers, by Application, Through 2024
    • Table 28: Asia-Pacific Market for Predisposition Biomarkers, by End User, Through 2024
    • Table 29: Cancer Incidence and Mortalities in Asia-Pacific, 2018
    • Table 30: Active Dementia Research Grants in Australia
    • Table 31: Rest of the World Market for Predisposition Biomarkers, by Application, Through 2024
    • Table 32: Rest of the World Market for Predisposition Biomarkers, by End User, Through 2024
    • Table 33: Number of Patents, by Country, January 2015-May 2019
    • Table 34: Number of Patents, by Company/Organization
    • Table 35: Number of Patents Registered, by Year
    • Table 36: BioMerieux Inc.: Financial Analysis, 2017 and 2018
    • Table 37: F. Hoffmann-La Roche Ltd.: Financial Analysis, 2017 and 2018
    • Table 38: Merck KGaA: Financial Analysis, 2017 and 2018
    • Table 39: QIAGEN N.V.: Financial Analysis, 2017 and 2018
    • Table 40: Thermo Fisher Scientific Inc.: Financial Analysis, 2017 and 2018
    • Table 41: Myriad Genetics Inc.: Financial Analysis, 2017 and 2018

List of Figures

  • Summary Figure: Global Market for Predisposition Biomarkers, by Application, 2018-2024
    • Figure 1: Global New Cancer Cases, by Type, 2018
    • Figure 2: Prevalence of Cancer, by Type, 2018
    • Figure 3: BioMerieux Inc.: Revenue, by Region, 2018
    • Figure 4: F. Hoffmann-La Roche Ltd.: Revenue, by Operating Segment, 2018
    • Figure 5: Merck KGaA: Revenue, by Region, 2018
    • Figure 6: QIAGEN N.V.: Revenue, by Region, 2018
    • Figure 7: Thermo Fisher Scientific Inc.: Revenue, by Region, 2018
    • Figure 8: Myriad Genetics Inc.: Revenue, by Operating Segment, 2018
目次
Product Code: BIO194A

Report Highlights:

This comprehensive report provides an in-depth assessment of the global market for predisposition biomarker technologies. The report’s key objective is to analyze areas of opportunities, key developments and the impact of this technology on industry, specifically the pharmaceutical, biotechnology and healthcare sectors. The analysis also reviews the adoption of predisposition biomarker technologies in developed and emerging markets.

Report Includes:

  • An overview of technologies and global markets for the predisposition biomarkers
  • Analyses of the global market trends with data from 2018, estimates for 2019, and projections of compound annual growth rates (CAGRs) through 2024
  • Information on recent key technical advances in different predisposition biomarkers, as well as the extent of adoption by commercial customers and regulatory authorities
  • Identification of key areas of growth and the key strategies of major players in the market
  • A look at recent diagnostic test developments and revelations as well as knowledge of how they will influence selected clinical markets

Table of Contents

Chapter 1: Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • BCC Custom Research
  • Related BCC Research Reports

Chapter 2: Summary and Highlights

Chapter 3: Market and Technology Background

  • Market Definition
    • Key Takeaways
    • Key Recommendations

Chapter 4: Market Breakdown by End User

  • Hospitals
  • Research Institutes

Chapter 5: Market Breakdown by Application

  • Cancer
  • Neurological Diseases
  • Cardiovascular Diseases
  • Diabetes
  • Other Diseases

Chapter 6: Market Breakdown by Region

  • North America
    • United States
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Rest of Asia-Pacific
  • Rest of World

Chapter 7: Patent Review and New Developments

    • Recent Developments

Chapter 8: Competitive Landscape

  • BioMerieux Inc.
    • Recent Developments
  • F. Hoffmann-La Roche Ltd.
    • Recent Developments
  • Merck KGaA
    • Recent Developments
  • QIAGEN N.V.
    • Recent Developments
  • Thermo Fisher Scientific Inc.
    • Recent Developments
  • Myriad Genetics Inc.
    • Recent Developments

Chapter 9: Company Profiles

  • ABCODIA LTD.
  • ADMERA HEALTH
  • ADX NEUROSCIENCES NV
  • AMPRION INC.
  • BIO-RAD LABORATORIES INC.
  • COMPUGEN LTD.
  • EPIGENOMICS AG
  • MIRNAXBIOSENS, S.L
  • ONCIMMUNE LTD.
  • OPTOS PLC
Back to Top